Achieve Life Sciences, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsAchieve Life Sciences is a late-stage specialty pharmaceutical company developing cytisinicline for nicotine dependence, currently navigating FDA resubmission after a Complete Response Letter.
What they do
Achieve Life Sciences is focused on the development and commercialization of cytisinicline as a treatment for nicotine dependence. The company has completed Phase 3 trials (ORCA-2 and ORCA-3) and a long-term safety study (ORCA-OL). It has no approved products and no revenue.
Revenue drivers
- Cytisinicline — The only product candidate; potential revenue from U.S. commercial launch following FDA approval. No sales to date.
Recent performance
For the second quarter of 2026, the company reported a net loss of $54.6 million for the full year 2025, and cash of $48.0 million as of June 30, 2026. The company received a Complete Response Letter from the FDA on June 20, 2026, related to manufacturing observations and labeling, with no efficacy or safety deficiencies. It has raised up to $354 million in a private placement, with $180 million upfront. Shareholder equity was negative $14.7 million as of June 30, 2026.
Strategy
The company is transitioning finished drug product manufacturing to U.S.-based Adare Pharma Solutions and plans to resubmit its NDA in Q4 2026. It is building a commercial team, with hires from Verona Pharma's Ohtuvayre launch, and has expanded its board with six new directors. Management emphasizes commercial readiness ahead of a potential FDA approval in the first half of 2027.
Risks
- FDA approval delay — NDA resubmission is planned for Q4 2026, but approval timing could slip beyond the first half of 2027.
- Manufacturing transition risk — The CRL cited cGMP issues at the prior facility; successful transfer to Adare is critical and not yet fully completed.
- Negative equity and cash burn — The company has negative shareholder equity and significant operating losses, relying on recent financing for liquidity.
- Commercial execution risk — If approved, the company must compete in the nicotine dependence market with limited commercial experience, though it has hired launch veterans.
Outlook
Management anticipates NDA resubmission in Q4 2026 and potential FDA approval in the first half of 2027, followed by U.S. commercial launch. The company has completed the technology transfer to Adare and produced its first engineering batch. With the new financing and team in place, focus is on resubmission and commercial readiness.